Kriya to Present 10 Abstracts at the 2023 American Society of Gene and Cell Therapy Annual Meeting
May 02, 2023 04:30 PM Eastern Daylight Time
PALO ALTO, Calif. & RESEARCH TRIANGLE PARK, N.C. – (BUSINESS WIRE)–Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced that it will present 10 abstracts at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place in Los Angeles, CA, May 16 – 20, 2023.
Our team has made significant progress in areas critical to the development, manufacturing, and characterization of gene therapies, and we look forward to presenting at this year’s ASGCT.
Kriya’s abstracts include two oral presentations and eight posters on its core technology and manufacturing platforms as well as its diverse pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases.
“We are excited to share updates as we continue to advance our diverse pipeline of gene therapies,” said Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya. “Our team has made significant progress in areas critical to the development, manufacturing, and characterization of gene therapies, and we look forward to presenting at this year’s ASGCT.”
The presentations include:
Oral Presentations:
Title: Analysis of Mechanisms Driving Improved Adeno-Associated Vector Production by the Addition of Small Molecules
Presenter: Nicholas Dietrich, Ph.D.
Session Date/Time: May 17 at 4:00 p.m. PT
Location: Concourse Hall 152 & 153
Abstract number: 47
Title: A Rapid, Serotype Specific Approach to AAV Formulation Development
Presenter: Robert Damitz, Ph.D.
Session Date/Time: May 18 at 2:00 p.m. PT
Location: Concourse Hall 150 & 151
Abstract number: 111
Poster Presentations:
Title: Sensitivity of AAV to Chemical and Physical Changes from Different Degradation Pathways
Presenter: Robert Damitz, Ph.D.
Session Date/Time: May 17 at 12:00 p.m. PT
Abstract number: 401
Title: Transcriptomic Profiling of Glycogen Storage Disease Type IX G2 Mouse Liver and Matched Plasma to Identify Biomarkers for Gene Therapy
Presenter: Sasha Makohon-Moore, Ph.D.
Session Date/Time: May 17 at 12:00 p.m. PT
Abstract number: 640
Title: Durability of AAV-Mediated Phenotypic Correction of Very Long-Chain Acyl-Coa Dehydrogenase (VLCAD) Deficiency in Mice
Presenter: Pilar Prentiss, M.S.
Session Date/Time: May 18 at 12:00 p.m. PT
Abstract number: 1156
Title: Optimizing Viral Genome Titer Methods: A Case Study on Improving Titer Accuracy Using ITR
Presenter: Rosalie Bateson
Session Date/Time: May 18 at 12:00 p.m. PT
Abstract number: 1232
Title: AAV Mediated Expression of a Chimeric Ion Channel in Combination with its Ligand Varenicline Demonstrates a Dose Response Improvement in Pain Hypersensitivity in a Rat Model of Trigeminal Pain
Presenter: Rosemarie Roeloffs, Ph.D.
Session Date/Time: May 19 at 12:00 p.m. PT
Abstract number: 1292
Title: Automated Monitoring, Analytics, and Machine-Learning for Improved Large Scale AAV Vector Production
Presenter: Mark Miller, Ph.D.
Session Date/Time: May 19 at 12:00 p.m. PT
Abstract number: 1302
Title: A Cell-Based Potency Method to Assess the Impact of Forced Degradation Methods on AAV Drug Product
Presenter: Lakmini Wasala, Ph.D.
Session Date/Time: May 19 at 12:00 p.m. PT
Abstract number: 1361
Title: Development of Adeno-Associated Virus Producer Cell Lines by Small Molecule Inducible Expression of Packaging Genes
Presenter: Nicholas Dietrich, Ph.D.
Session Date/Time: May 19 at 12:00 p.m. PT
Abstract number: 1580
About Kriya Therapeutics
Kriya Therapeutics, Inc. is a biopharmaceutical company developing gene therapies for diseases affecting millions of people around the world. With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $450 million to advance a broad pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases. For more information, please visit www.kriyatx.com and follow on LinkedIn and Twitter.
Contacts
Ryan Flinn, VP, Head of Communications
Kriya Therapeutics, Inc.
Rflinn@kriyatx.com
510−207−7616